Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF). Our results indicate that very small inhaled doses deliver oral-superior, but short-lived lung levels. To understand if this increased lung dose may improve IPF efficacy, we further demonstrated that only short-lived lung levels are required for maximum pirfenidone activity. Moreover, because these inhaled doses are small, it is anticipated that oral-observed side effects will be substantially reduced. In addition to these observations, characterization of the pirfenidone mechanism suggests that the drug inhibits a single, upstream pro-fibrotic target with strong influence on downstream pathways critical for IPF initiation and disease progression (manuscript in preparation).

"These results further support inhalation as the optimal method to administer pirfenidone to achieve maximum IPF efficacy in a safe and well-tolerated medicine," said Mark Surber, Ph.D., Genoa's President and Chief Executive Officer. "In addition to laying the foundation for successful GP-101 clinical design, these collaborative studies have also expanded our understanding of IPF disease progression and identified a family of additional therapeutic targets."

"Discovery that pirfenidone may inhibit a particular IPF target shown to influence several downstream pathways is important for it may explain some of pirfenidone's effect; showing that inhalation enables improved activity against this important target further justifies this therapeutic approach," said Dr. Martin Kolb, M.D., Ph.D. & Associate Professor in the Division of Respirology, within the Department of Medicine Pathology & Molecular Medicine at McMaster University.  "We are excited to continue our productive collaboration with Genoa, and with these results enter these activities with an increased enthusiasm for GP-101's potential to positively impact the lives of people with this devastating disease."